AXL-Receptor Targeted 14FN3 Based Single Domain Proteins (Pronectins™) from 3 Synthetic Human Libraries as Components for Exploring Novel Bispecific Constructs against Solid Tumors
Open Access
- 8 December 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (12) , 3184
Abstract
A highly specific AXL-receptor targeted family of non-immunoglobulin, single domain protein binders (Pronectins™) have been isolated from three (3) synthetic libraries that employ the human scaffold of the 14th domain of Fibronectin III (14FN3) and evolutionary CDRs diversity of over 25 billion loop sequences. The three libraries, each containing diversity in two loops, were designed to expand upon a human database of more than 6000 natural scaffold sequences and approximately 3000 human loop sequences. We used a bioinformatic-based approach to maximize “human” amino acid loop diversity and minimize or prevent altogether CDR immunogenicity created by the use of mutagenesis processes to generate diversity. A combination of phage display and yeast display was used to isolate 59 AXL receptor targeted Pronectins with KD ranging between 2 and 100 nM. FACS analysis with tumor cells over-expressing AXL and the use of an AXL knock-out cell line allowed us to identify Pronectin candidates with exquisite specificity for AXL receptor. Based upon several in vitro cell-based tests, we selected the best candidate, AXL54, to further characterize its in vitro cancer cells killing activity. Finally, AXL54 was used to produce the first bi-specific T cell engager protein (AXL54 [Pronectin]-linker-scFV CD3), a “new in class” protein for further testing of its anti-tumor activity in vitro and in vivo.Keywords
This publication has 43 references indexed in Scilit:
- Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human FibronectinClinical Cancer Research, 2011
- Adnectins: engineered target-binding protein therapeuticsProtein Engineering, Design and Selection, 2010
- Advances in generating functional diversity for directed protein evolutionCurrent Opinion in Chemical Biology, 2009
- Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor twoProtein Engineering, Design and Selection, 2005
- PDL's mAb technology finds right timingNature Biotechnology, 2001
- Modeling of loops in protein structuresProtein Science, 2000
- The fibronectin type III domain as a scaffold for novel binding proteinsJournal of Molecular Biology, 1998
- Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domainNature Biotechnology, 1997
- Comparative Protein Modelling by Satisfaction of Spatial RestraintsJournal of Molecular Biology, 1993
- Filamentous Fusion Phage: Novel Expression Vectors That Display Cloned Antigens on the Virion SurfaceScience, 1985